Jiangsu Ambition In-licenses Prostate Treatment from Sweden's Lidds

02:44 EDT 17 May 2018 | ChinaBio Today

Jiangsu Ambition Medical has in-licensed China rights to a prostate treatment that is delivered via an injected depot system, which administers the drug directly to the tumor for up to six months. Sweden's Lidds AB developed Liproca® Depot and is currently conducting a Phase IIb trial in Finland and Canada. Ambition will pay $1 million upfront, plus milestones and royalties for China rights. It will also be responsible for securing China regulatory approval, which may be the first approval for Liproca globally. More details....

Share this with colleagues:

Original Article: Jiangsu Ambition In-licenses Prostate Treatment from Sweden's Lidds


More From BioPortfolio on "Jiangsu Ambition In-licenses Prostate Treatment from Sweden's Lidds"

Quick Search


Relevant Topics

Benign Prostatic Hyperplasia (BPH)
An enlarged prostate (benign prostatic enlargement (BPE) or benign prostatic hyperplasia (BPH)) is common in men after the age of about 50. Having an enlarged prostate does not mean you have cancer. In some cases, an enlarged prostate can cause the ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...